Business Wire

New Fitness, Sports, and Health Devices Using Movesense Motion Sensing Technology to Be Featured at CES 2018 with Suunto

Jaa

One year after introducing Movesense beta at CES, close to 400 developers around the world have access to Suunto’s all-in-one motion sensor, including four companies that will present their products at CES 2018. Now Suunto has released Movesense firmware version 1.0, and has ramped up production capabilities to meet growing demand from companies integrating Movesense in their products. The companies will unveil the products at booth 44337 in the Fitness and Technology Marketplace.

The Movesense sensor accelerates the time to market for everything from fitness wearables to health monitoring devices to livestock trackers to university research. At just 1.44 inches in diameter and 0.35 ounces, Movesense combines an accelerometer, gyroscope, magnetometer, temperature sensor, heart rate, and ECG sensor in a pre-built package that can be white-labeled and quickly integrated in virtually any device or garment.

“The world has already seen many motion sensors, but none as easy to customize for your own project as the Movesense sensor. Most IoT motion sensors are either cost-prohibitive industrial-grade options or they’re incomplete circuit boards that aren’t ready to use,” said Terho Lahtinen, Senior Manager, Future Concepts at Movesense. “With Movesense, we’re sharing our hardware development experience with companies to help them shave years off the R&D process. Hundreds of businesses—both startups and established companies—already have access to Movesense. With its well-managed API, these companies can build new sensor functionality to quickly commercialize their own sensor concepts. In a sense, we’re democratizing the development of sensor functions. Companies will be able to generate comprehensive data that can improve athletic performance, spot equipment failures, aid rehabilitation programs, and support virtually any motion-sensing application you can dream up.”

The companies unveiling new products based on the Movesense platform include:

Ain1.ai : A human performance and measurement application. Until recently, professionals relied on bulky, expensive equipment to monitor the progress of training or rehabilitation. Ain1, a Finnish startup focused on human performance, is developing a novel, lightweight, mobile platform with the Movesense sensor for coaching and rehabilitation use.

A patient or an athlete completes a set of movements or exercises while wearing the device, which captures precise measurements previously unavailable to healthcare professionals or coaches. With the data, the progress can be monitored and documented accurately and objectively. The first product of the Ain1 product family, Ain1 Balance, will be announced at CES.

Runteq : Intelligent running exercise and technique coach. Runteq helps recreational runners monitor their running load/power and running economy, improve their running technique, and prevent overload injury. Runteq, a Finnish fitness tech company, introduces its new Movesense-based wearable product and its game-changing, cloud-based coaching app that treats every runner as an individual and combines cool running technique findings with personal feelings and sensations.

Runteq programmed its proprietary running biomechanics algorithms into the Movesense sensors and is now benefiting from Suunto’s cutting edge software and hardware platforms. Instead of developing their own hardware, they can now put their full effort on developing running technique analysis and AI/ML-driven coaching experience.

SUPA: Body-sensing analytics kits featuring apparel. SUPA is a B2B modular, scalable, distributed, and secure biometric data platform for using sensors from distributed IoT devices including SUPA Powered apparel and Movesense sensors. SUPA offers SUPA kits for customers to develop new products and services. The kits are modularly designed on top of a core functionality, empowering distributed functionalities in sports, wellness, and health.

SUPA’s proprietary Artificial Intelligence contextualizes the biometric data to provide highly personalized insights for individuals as well as data analytics for SUPA’s B2B customers. SUPA’s mission is to build a secure vault of biometric data and democratizing healthcare.

TriMix : Tri-Fitness at home. New York based fitness-tech company TriMix has developed a connected “home gym” that streams live workout classes to users in their homes. The package includes cardio and strength training equipment, a tablet computer, and multiple Movesense sensors. The workout classes are personalized through an interactive app, driven by each user’s real-time heart rate and movement data. As such, the live workouts revolve around each individual, and are appropriate for all ages and fitness levels.

About Movesense

Movesense is an open development environment for motion-sensing solutions. Developed in Finland by Suunto, its easy and innovative tools accelerate measuring and sensing applications across sports, agriculture, manufacturing, health care, and more. Learn more at http://www.movesense.com.

Companies interested in incorporating Movesense motion-sensing technology into their prototypes or current products can order a developer kit today at www.movesense.com.

About Suunto

Suunto is a Finnish manufacturer of world renowned sports watches, dive computers and precision instruments for the toughest conditions. Find out more about the company and its products at www.suunto.com.

Contact information

Gregory FCA
Matt McLoughlin, 610-228-2123
Matt@GregoryFCA.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Manchester United and True Religion Launch Denim Range19.10.2018 20:37Tiedote

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10Tiedote

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00Tiedote

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 14:54Tiedote

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Tradeshift Announces Q3 2018 Results19.10.2018 14:00Tiedote

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 14:00Tiedote

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme